Method and probe set for detecting cancer
View Patent ↗Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if aneusomic cells are present in a selected subset of cells obtained from the biological sample are described. A set of chromosomal probes and kits for detecting cancer that include sets of chromosomal probes, are also described.
1. A method of monitoring a patient for cancer recurrence, said method comprising:
(a) hybridizing one set of chromosomal probes to a biological sample from said patient, wherein said set consists of centromeric probes to chromosomes 3, 7, and 17, and locus specific probe 9p21;
(b) selecting cells from said biological sample; and
(c) determining the presence or absence of aneusomic cells in said selected cells by examining the hybridization pattern of only said set of chromosomal probes in each of said selected cells, wherein the presence of aneusomic cells in said selected cells is indicative of cancer recurrence in said patient.
2. The method of claim 1 , wherein said biological sample is selected from the group consisting of urine, blood, cerebrospinal fluid, pleural fluid, sputum, peritoneal fluid, bladder washings, oral washings, tissue samples, touch preps, and fine-needle aspirates.
3. The method of claim 1 , wherein said biological sample is concentrated.
4. The method of claim 1 , wherein said biological sample is urine.
5. The method of claim 1 , wherein said cancer is selected from the group consisting of bladder cancer, lung cancer, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, renal cancer, and leukemia.
6. The method of claim 1 , wherein said cancer is bladder cancer.
7. The method of claim 1 , wherein said chromosomal probes are fluorescently labeled.
8. The method of claim 1 , wherein cells are selected by nuclear morphology.
9. The method of claim 1 , wherein cells are selected by nuclear size.
10. The method of claim 1 , wherein cells are selected by shape of nucleus.
11. The method of claim 8 , wherein nuclear morphology is assessed by DAPI staining.
12. A method of monitoring a patient undergoing cancer treatment, said method comprising:
(a) hybridizing one set of chromosomal probes to a biological sample from said patient, wherein said set consists of centromeric probes to chromosomes 3, 7, and 17, and locus specific probe 9p21;
(b) selecting cells from said biological sample; and
(c) determining the presence or absence of aneusomic cells in said selected cells by examining the hybridization pattern of only said set of chromosomal probes in each of said selected cells, wherein the presence of aneusomic cells in said selected cells is indicative of a continued need for treatment of said patient.
13. The method of claim 12 , wherein said biological sample is selected from the group consisting of urine, blood, cerebrospinal fluid, pleural fluid, sputum, peritoneal fluid, bladder washings, oral washings, tissue samples, touch preps, and fine-needle aspirates.
14. The method of claim 12 , wherein said cancer is selected from the group consisting of bladder cancer, lung cancer, breast cancer, ovarian cancer, prostate cancer, coloreetal cancer, renal cancer, and leukemia.
15. The method of claim 12 , wherein said cancer is bladder cancer.
16. A kit consisting of one set of chromosomal probes and optionally one or more reagents selected from the group consisting of a slide, phosphate buffered saline, hybridization buffer, 4,6-diamidino-2-phenylindole dihydroehloride (DAPI), sodium chloride-sodium citrate (SSC) solution, fixative, ethanol, non-ionic detergent, and denaturation buffer, said set of chromosomal probes consisting of three centromeric chromosomal probes and locus specific probe 9p21, wherein said three centromeric probes are centromerie probes to chromosomes 3, 7, and 17, wherein the probes are labeled such that each probe can be distinctly visualized after hybridization to a biological sample.